NYU Langone Health Establishes Center for Psychedelic Medicine
NYU Langone's psychedelic medicine center, its funding, and the conditions its trials set out to study.
Psilocybin articles
The articles moving decisions and thought in psilocybin law and science: regulator guidance, research center announcements, and reporting from leading publications. The studies themselves live in the research collection.
39 of 39 articles
Authoritative sources
14 on the shelfStraight from the regulators, health agencies, research centers, and companies whose decisions guide the industry, the legislation, and the science.
Imperial launches world's first Centre for Psychedelics Research
The launch of the first academic centre built for psychedelic research, and what it set out to do.
Psilocybin: A breakthrough in mental health treatment or mere 'magical' thinking?
A Yale psychiatrist on what the small psilocybin studies so far can and cannot show.
Published 23 Sep 2025
Psilocybin for Mental Health and Addiction: What You Need To Know
A federal explainer on psilocybin's risks, including who should not take it and its legal status.
Psychedelic and Dissociative Drugs as Medicines
Where federal science stands on psilocybin for depression, anxiety, alcohol use and smoking.
Published 24 Jan 2024
How Psychedelic Drugs Alter the Brain
What brain imaging showed after a single psilocybin dose, and how long the changes lasted.
Publisher blocks automated checks
First-of-Its-Kind Psychedelic Research Center Debuts at Johns Hopkins
How a $17 million donor gift started the Johns Hopkins psychedelic research center.
Publisher blocks automated checks
FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order
The agency's own account of the priority vouchers it issued to three psychedelic drug developers.
Published 24 Apr 2026
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
The developer's own topline readout from the first phase 3 psilocybin trial in treatment-resistant depression.
Publisher blocks automated checks
practitioner reference, not medical evidence
Psychedelic Drugs: Considerations for Clinical Investigations (Guidance for Industry)
The canonical guidance sponsors follow when designing a psilocybin trial, from psychotherapy to safety monitoring.
FDA Issues First Draft Guidance on Clinical Trials with Psychedelic Drugs
The announcement of the first draft guidance for researchers studying psychedelics as potential treatments.
Johns Hopkins Center for Psychedelic and Consciousness Research
The Johns Hopkins center's own page listing its psilocybin studies, faculty and research program.
Publisher blocks automated checks
FDA grants Breakthrough Therapy Designation to Usona Institute's psilocybin program for major depressive disorder
The nonprofit developer's record of the FDA breakthrough designation for its psilocybin depression program.
Publisher blocks automated checks
practitioner reference, not medical evidence
UCSF Translational Psychedelic Research (TrPR) Program
The UCSF program studying psilocybin therapy for depression and anxiety in people with Parkinson's disease.
Science and health reporting
16 on the shelfThe desks that cover this field week in and week out. Reporters who read the studies, call the researchers, and set out what actually changed.
Compass says its psilocybin drug helped patients with severe depression in two trials
Compass reports phase 3 depression results, and an outside psychiatrist weighs whether they meet the approval bar.
Published 17 Feb 2026
RFK, Jr., Puts Psychedelics on Fast Track to FDA Review and Approval
Why the FDA is expediting review of psilocybin and methylone programs after a presidential executive order.
Australia to prescribe MDMA and psilocybin for PTSD and depression in world first
Australia became the first country to let authorised psychiatrists prescribe psilocybin, and researchers questioned the pace.
Published 30 Jun 2023
Largest psilocybin trial finds the psychedelic is effective in treating serious depression
Remission rates from the largest psilocybin depression trial, alongside the serious adverse events reported.
Published 09 Nov 2021
Psilocybin Therapy May Work as Well as Common Antidepressant
Psilocybin therapy tested head to head against a common SSRI, with a split result across measures.
Shrooms Lead the Pack in Psychedelic Medicine, but Rollout Is Bumpy
Where legal psilocybin access actually stands in the United States, including closures and costs in Oregon.
Publisher blocks automated checks
Published 13 Jan 2026
New Zealand Approved Psychedelic Therapy. He's the Only Doctor Who Can Prescribe It.
New Zealand allowed prescribed psilocybin and then named one psychiatrist as the only doctor who can prescribe it.
Publisher blocks automated checks
Published 26 Jun 2025
Reeling from FDA setback, researchers plot the future of psychedelic-assisted medicine
Researchers on what the field must fix after the FDA advisory committee voted against MDMA therapy.
Publisher blocks automated checks
What Does Good Psychedelic Therapy Look Like?
What supervised psychedelic therapy actually involves, from preparation sessions to dosing to integration afterward.
Publisher blocks automated checks
Published 03 Jun 2023
The psychedelic escape from depression
The argument that a few psilocybin doses may produce durable relief, and where that evidence falls short.
Published 28 Sep 2022
Psychedelic drugs take on depression
Why blinding participants is nearly impossible in psilocybin trials, and what that does to the evidence.
Published 24 Aug 2022
The Promises and Perils of Psychedelic Health Care
A survey of the psychedelic medicine boom, weighing early research optimism against safety, access and hype.
Publisher blocks automated checks
Published 05 Jan 2022
Psilocybin Helps Alleviate Depression Symptoms, Small Study Says
Brain scans from two depression trials showed increased connectivity, findings the reporting frames as early and small.
Publisher blocks automated checks
Published 11 Apr 2022
Psychedelic-inspired drugs could relieve depression without causing hallucinations
Mouse research suggesting the antidepressant effect and the trip may run on separate pathways.
Publisher blocks automated checks
Executive order aims to speed psychedelic research
What the executive order on psychedelics directs the FDA to do, and the money behind it.
Publisher blocks automated checks
Daily briefing: Largest trial shows psilocybin is effective to treat depression
A short briefing on the trial headline, noting the results came by press release before peer review.
Published 10 Nov 2021
Features and essays
9 on the shelfGeneral-audience writing: long features, profiles, and first-person accounts. Worth reading for how the field has been talked about, and not a source of evidence about what psilocybin does.
Magic mushrooms' psilocybin can alleviate severe depression when used with therapy
The largest psilocybin depression trial to date, including how many kept the benefit at twelve weeks.
Published 02 Nov 2022
The Trip Treatment
Michael Pollan's feature that brought psilocybin therapy for cancer patients to a mainstream audience.
The New Science of Psychedelic Drugs
Researchers are re-engineering psilocybin to control how long and how intensely a session runs.
Published 12 Jun 2026
A dose of psilocybin helps smokers quit in new study
A single psilocybin dose tested against the nicotine patch for quitting smoking, with results the authors call preliminary.
Published 10 Mar 2026
Psychedelic Therapy Crashed and Burned. MAHA Might Bring It Back
How the field stalled after the FDA declined MDMA therapy, and which officials are pushing it back.
Published 29 Jul 2025
The Magic and Mystery of Psychedelic Therapies
Inside the Columbia labs running psilocybin and LSD trials for depression and anxiety.
The Uncertain Path Forward for Psychedelic Medicine
What the FDA's rejection of MDMA therapy meant for the companies still working on psilocybin.
Published 15 Aug 2024
People Are Trying Magic Mushrooms for Depression - and Accidentally Meeting God
People who took mushrooms for depression and came back describing religious experiences instead.
Published 18 Aug 2024
Psychedelics are transforming the way we understand depression and its treatment
Robin Carhart-Harris argues his psilocybin research points to a different way of understanding depression.
Published 20 Apr 2021
About this shelf
These are third-party articles about psilocybin research and law, not the research itself. The primary studies sit in a separate corpus of 75 papers in the research collection, and nothing on this shelf is cited as evidence in the register.
This is a reading list, not medical advice: each note reports what an article says, with its publisher and year, and makes no medical claims. How entries are chosen and checked is set out in the methodology.
One further entry is held off the shelf: the copy on file sits on a re-publisher, not the original, and it stays off until a primary or licensed archive is on the record.
The works listed here are third-party publications, included for reference. Listing is not endorsement, and nothing here is a medical or efficacy claim. Rights holders can request removal at any time.
Every title links to its rightsholder; preview images are stored at small scale and used only to identify the piece being linked. Rights holders can request removal. Nothing here carries an affiliate tag.